Newly Arrival 4-Biphenylcarboxylic Acid (92-92-2)

With our outstanding administration, powerful technical capability and strict top quality handle procedure, we go on to provide our purchasers with reliable good quality, reasonable selling prices and excellent services. We goal at becoming certainly one of your most responsible partners and earning your gratification for Newly Arrival 4-Biphenylcarboxylic Acid (92-92-2), The principle of our corporation is always to give high-quality merchandise, expert service, and honest communication. Welcome all friends to place trial get for making a long-term enterprise partnership.
With our outstanding administration, powerful technical capability and strict top quality handle procedure, we go on to provide our purchasers with reliable good quality, reasonable selling prices and excellent services. We goal at becoming certainly one of your most responsible partners and earning your gratification for China Organic Synthesis Intermediates, Our merchandise are mainly exported to Southeast Asia, the Middle East, North America and Europe. Our quality is surely guaranteed. If you are interested in any of our goods or would like to discuss a custom order, make sure you feel free to contact us. We are looking forward to forming successful business relationships with new clients around the world in the near future.

2′-hydroxy-3′-nitro-3-biphenylcarboxylic acid is used as the intermediate of Eltrombopag .
Eltrombopag, developed by GlaxoSmithKline (GSK) in the UK and later jointly developed with Novartis in Switzerland, is the first and only approved small molecule non peptide TPO receptor agonist in the world. Eltrombopag was approved by the US FDA in 2008 for the treatment of idiopathic thrombocytopenic purpura (ITP), and in 2014 for the treatment of severe aplastic anemia (AA). It is also the first drug approved by the US FDA for the treatment of AA in recent 30 years.
In december2012, the US FDA approved Eltrombopag for the treatment of thrombocytopenia in patients with chronic hepatitis C (CHC), so that hepatitis C patients with poor prognosis due to low platelet count can start and maintain interferon based standard therapy for liver diseases. On february3,2014, GlaxoSmithKline announced that the FDA granted the breakthrough treatment drug qualification of Eltrombopag for the treatment of hemopenia in patients with severe chemicalbook aplastic anemia (SAA) who did not fully respond to immunotherapy. On August 24, 2015, the US FDA approved Eltrombopag for the treatment of thrombocytopenia in adults and children aged 1 year and over with chronic immune thrombocytopenia (ITP) who have insufficient response to corticosteroids, immunoglobulins or splenectomy. On january4,2018, Eltrombopag was approved to be listed in China for the treatment of primary immune thrombocytopenia (ITP).

With our outstanding administration, powerful technical capability and strict top quality handle procedure, we go on to provide our purchasers with reliable good quality, reasonable selling prices and excellent services. We goal at becoming certainly one of your most responsible partners and earning your gratification for Newly Arrival 4-Biphenylcarboxylic Acid (92-92-2), The principle of our corporation is always to give high-quality merchandise, expert service, and honest communication. Welcome all friends to place trial get for making a long-term enterprise partnership.
Newly Arrival China Organic Synthesis Intermediates, Our merchandise are mainly exported to Southeast Asia, the Middle East, North America and Europe. Our quality is surely guaranteed. If you are interested in any of our goods or would like to discuss a custom order, make sure you feel free to contact us. We are looking forward to forming successful business relationships with new clients around the world in the near future.